Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “alcohol” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 117
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 117 pipeline programs matching "alcohol" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

117 results for “alcohol” Back to intelligence hub

Search results

Page 1 of 5
  1. AD04 (ondansetron)

    ADIAL PHARMACEUTICALS, INC.

    Alcohol Use Disorder

    phase 3 small molecule completed

    1 trial
  2. Aramchol free acid

    Galmed Pharmaceuticals

    Nonalcoholic Steatohepatitis (NASH)

    phase 3 small molecule on hold

    1 trial
  3. Bias retraining

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol Use Disorder

    phase 3 other completed

    1 trial
  4. C24-50

    The George Institute

    Semantic Variant Primary Progressive Aphasia, Alcohol Use Disorder, Organic amnesia syndrome, Narcolepsy, Alzheimer, Lewy Body Dementia

    phase 3 small molecule active

    1 trial
  5. Eltrombopag

    GlaxoSmithKline

    Non-alcoholic Steatohepatitis

    phase 3 small molecule terminated

    1 trial
  6. Gabapentin 300mg

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol Drinking

    phase 3 small molecule completed

    1 trial
  7. J2S-MC-GZME

    Eli Lilly Co.

    Alcohol Use Disorder

    phase 3 small molecule active

    1 trial
  8. METHYLPREDNISOLONE , ACETYLCYSTEINE

    The George Institute

    Acute Alcoholic hepatitis

    phase 3 small molecule active

    1 trial
  9. MGL-3196

    Madrigal Pharmaceuticals EU Limited

    NASH - Nonalcoholic Steatohepatitis

    phase 3 small molecule active

    1 trial
  10. MGL-3196-11

    Madrigal Pharmaceuticals EU Limited

    Non-Alcoholic Steatohepatitis (NASH)

    phase 3 small molecule active

    1 trial
  11. MGL-3196-19

    Madrigal Pharmaceuticals EU Limited

    Non-alcoholic Steatohepatitis (NASH) Cirrhosis

    phase 3 small molecule active

    1 trial
  12. NN9931-4553

    NovoThirteen

    Non-alcoholic steatohepatitis (NASH)

    phase 3 small molecule active

    1 trial
  13. Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Alcoholism

    phase 3 small molecule completed

    1 trial
  14. Placebo

    Madrigal Pharmaceuticals EU Limited

    Non-Alcoholic Fatty Liver Disease

    phase 3 small molecule completed

    1 trial
  15. Placebo

    Tobira Therapeutics

    Nonalcoholic Steatohepatitis

    phase 3 small molecule terminated

    1 trial
  16. Progesterone

    United Therapeutics Europe Ltd

    Alcohol Dependence

    phase 3 small molecule completed

    1 trial
  17. Resmetirom

    Madrigal Pharmaceuticals EU Limited

    Non-Alcoholic Fatty Liver Disease

    phase 3 small molecule active

    1 trial
  18. SIMFIB

    The George Institute

    Fibrosis liber, chronic liver disease, alcoholic liver disease

    phase 3 small molecule active

    1 trial
  19. 0.9% Sodium Chloride Injection

    GlaxoSmithKline

    Non-alcoholic Fatty Liver Disease

    phase 2 small molecule active

    1 trial
  20. 222291

    GlaxoSmithKline

    Liver Diseases, Alcoholic

    phase 2 other active

    1 trial
  21. 30% Nitrous oxide

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol-Related Disorders

    phase 2 small molecule completed

    1 trial
  22. 5 mg/kg CM-101

    Chemomab Therapeutics

    Nonalcoholic Steatohepatitis

    phase 2 mab completed

    1 trial
  23. ADX-629

    Aldeyra Therapeutics

    Alcohol Hepatitis

    phase 2 small molecule completed

    1 trial
  24. ARO-HSD Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Non-alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.